Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Nissay Asset Management Corp Japan ADV

Nissay Asset Management Corp Japan ADV lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,573 shares of the biopharmaceutical company’s stock after selling 4,801 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Gilead Sciences were worth $12,410,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Gilead Sciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 23,848,477 shares of the biopharmaceutical company’s stock valued at $2,044,282,000 after purchasing an additional 244,886 shares during the period. FMR LLC increased its stake in shares of Gilead Sciences by 27.2% in the first quarter. FMR LLC now owns 20,909,082 shares of the biopharmaceutical company’s stock valued at $1,734,826,000 after purchasing an additional 4,470,179 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after purchasing an additional 13,764,169 shares during the period. Morgan Stanley increased its stake in shares of Gilead Sciences by 11.5% during the fourth quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock valued at $1,476,358,000 after acquiring an additional 1,780,489 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Gilead Sciences by 2.8% during the first quarter. Bank of New York Mellon Corp now owns 17,012,204 shares of the biopharmaceutical company’s stock valued at $1,411,503,000 after acquiring an additional 466,595 shares during the period. Institutional investors and hedge funds own 82.33% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $76.00 on Monday. The company has a market capitalization of $94.70 billion, a PE ratio of 17.47, a price-to-earnings-growth ratio of 0.83 and a beta of 0.37. Gilead Sciences, Inc. has a one year low of $61.44 and a one year high of $89.74. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.02 and a quick ratio of 0.91. The company’s fifty day moving average price is $77.22 and its 200 day moving average price is $78.93.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $1.34 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.30). Gilead Sciences had a return on equity of 37.53% and a net margin of 20.03%. The firm had revenue of $6.60 billion during the quarter, compared to the consensus estimate of $6.45 billion. During the same quarter last year, the business earned $1.58 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. As a group, analysts expect that Gilead Sciences, Inc. will post 6.63 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $3.00 annualized dividend and a dividend yield of 3.95%. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.97%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on GILD shares. Truist Financial reiterated a “buy” rating and set a $91.00 price objective on shares of Gilead Sciences in a research note on Wednesday, September 6th. Cantor Fitzgerald lowered their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 19th. Piper Sandler lowered their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, July 24th. Morgan Stanley raised their price objective on shares of Gilead Sciences from $86.00 to $88.00 and gave the company an “equal weight” rating in a research note on Friday, August 4th. Finally, Royal Bank of Canada raised their target price on shares of Gilead Sciences from $83.00 to $84.00 and gave the stock a “sector perform” rating in a report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $90.05.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 1,485 shares of the business’s stock in a transaction dated Tuesday, June 13th. The shares were sold at an average price of $76.90, for a total value of $114,196.50. Following the transaction, the insider now directly owns 29,402 shares in the company, valued at $2,261,013.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the chief financial officer now directly owns 107,587 shares of the company’s stock, valued at $8,606,960. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 1,485 shares of the business’s stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $76.90, for a total transaction of $114,196.50. Following the sale, the insider now directly owns 29,402 shares of the company’s stock, valued at $2,261,013.80. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.